医学
弗莱卡奈德
室上性心动过速
地高辛
心动过速
不利影响
胺碘酮
经胎盘
索他洛尔
麻醉
怀孕
心脏病学
胎儿
内科学
重症监护医学
心房颤动
心力衰竭
生物
胎盘
遗传学
作者
Isabelle Malhamé,Christy Gandhi,Gofran Tarabulsi,Matthew A. Esposito,Kristin Lombardi,Antony Chu,Kenneth K. Chen
标识
DOI:10.1177/1753495x18808118
摘要
Fetal tachycardia is a rare complication during pregnancy. After exclusion of maternal and fetal conditions that can result in a secondary fetal tachycardia, supraventricular tachycardia is the most common cause of a primary sustained fetal tachyarrhythmia. In cases of sustained fetal supraventricular tachycardia, maternal administration of digoxin, flecainide, sotalol, and more rarely amiodarone, is considered. As these medications have the potential to cause significant adverse effects, we sought to examine maternal safety during transplacental treatment of fetal supraventricular tachycardia. In this narrative review we summarize the literature addressing pharmacologic properties, monitoring, and adverse reactions associated with medications most commonly prescribed for transplacental therapy of fetal supraventricular tachycardia. We also describe maternal monitoring practices and adverse events currently reported in the literature. In light of our findings, we provide clinicians with a suggested maternal monitoring protocol aimed at optimizing safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI